NINTEDANIB

Nintedanib is a tyrosine kinase inhibitor used in the treatment of certain pulmonary and fibrotic conditions. It exerts its effects by targeting multiple receptors, including those involved in fibroblast proliferation and vascular remodeling.

Indications

-Nintedanib is indicated for the treatment of idiopathic pulmonary fibrosis (IPF) and systemic sclerosis-associated interstitial lung disease (SSc-ILD). It is prescribed to slow down the decline in lung function and improve overall respiratory outcomes in these conditions. -Treatment of idiopathic pulmonary fibrosis (IPF), Treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype, Slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD)

Dosage

-The recommended dosage of nintedanib is typically 150 mg orally twice daily with food. Dosage adjustments may be necessary based on individual patient factors and tolerability. -Recommended dosage: 150 mg taken orally twice daily approximately 12 hours apart taken with food.

Contra-Indications

-Nintedanib is contraindicated in patients with a known hypersensitivity to the drug or its components. It should not be used in individuals with severe hepatic impairment. -Hypersensitivity

Special Precautions

-Liver function should be monitored regularly during treatment. -Use caution in patients with a history of bleeding disorders. -Pregnancy and breastfeeding: Nintedanib may cause fetal harm, and its use is not recommended during pregnancy or lactation. Paediatric: Safety and efficacy in pediatric patients have not been established Pregnancy: Data not sufficient Lactation: Breast feeding is not recommended Elderly: No overall differences in safety or effectiveness have been observed between elderly and other adult patients.

Side Effects

-Common side effects include diarrhea, nausea, fatigue, rash, and elevated liver enzymes. Severe adverse reactions such as bleeding, gastrointestinal perforations, and liver toxicity may occur but are rare. -Diarrhea, Nausea, Vomiting, Skin ulcer. Abdominal pain, Liver enzyme elevation, Weight decreased, Fatigue, Decreased appetite, Headache, Pyrexia, Back pain, Dizziness, Hypertension

Drug Interactions

-Nintedanib may interact with CYP3A4 inducers or inhibitors, potentially affecting its plasma concentration. Concurrent use with anticoagulants or antiplatelet agents may increase the risk of bleeding. -Rifampicin, anticoagulants